David Sans

The Wall Street Journal — TEL AVIV, Israel and BETHESDA, Md., Sept. 22, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the Company will present at the 4(th) Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston.

PR Newswire — SAN FRANCISCO, Sept. 5, 2012 /PRNewswire/ -- Merriman Capital, Inc., a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), today announced the addition of health care investment banker David Sans, Ph.D. to its Financial Entrepreneur Platform (FEP).

www.c3healthcare2014.com — Investors - Dr. Al-Razouki has advised (and co-invested through Kleos) into lucrative healthcare opportunities. The returns of his investments have been consistently above 30% and range from acquisitions of leading regional hospitals, clinics, wellness centers, online healthcare services, to pharma education Service Providers - Dr. Al-Razouki has developed growth strategies for the GCC's leading hospital brands and has championed due diligences for private equity companies aiming to acquire profitable healthcare assets.

BioSpace — CALGARY, Alberta, Aug. 07, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc.. ("XORTX" or the "Company") (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Dr. David Sans as Director, Corporate Development to be based in New York City.

GlobeNewswire — CALGARY, Alberta, Aug. 07, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Dr. David Sans as Director, Corporate Development to be based in New York City.

Ocean City Today — TEL AVIV, Israel and BETHESDA, Md., Sept. 22, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the Company will present at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston .

Capital Press — TEL AVIV, Israel and BETHESDA, Md., Sept. 22, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the Company will present at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston .

accesswire.com — Why David Sans in New York Believes Axonal Transport Can Be Key to Helping People with Alzheimer's NEW YORK, NY / ACCESSWIRE / October 1, 2021 / David Sans is a noted investor and a philanthropist in the healthcare industry.

Business Wire — LA JOLLA, Calif.--()-- Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, today announced the appointment of David Sans, FAARM, Ph.D, MBA, in New York as Head of Corporate Development.

calidibio.com — Chief Executive Officer Chairman of the Board of Directors

StreetInsider.com — “We are thrilled to welcome David to the Calidi team as we continue to broaden our bench of executive talents” Calidi Biotherapeutics Appoints David Sans, FAARM, Ph.D., MBA, as Head of Corporate Development Dr. Sans brings over two decades of life sciences experience spanning investment banking, corporate development, and clinical research